Boston Scientific: Navigating 2026 Headwinds with a Path to Recovery
Boston Scientific (BSX) has been pummeled since its 52-week high but still sits on solid fundamentals: $80.6B market cap, $3.62B free cash flow and a diversified device franchise exposed to multiple secular growth markets. Management's recent insider purchase and a $500M restructuring initiative point to near-term stabilization. This trade idea out…